Amgen Inc. is a drug manufacturing company incorporated in 1980. Venture capitalists William Bowes and others conceived the idea for Applied Molecular Genetics, Inc. with only three people as staff. In its first months of operation, AMGen Inc. received overwhelming support from investors and embarked on innovative genetic engineering. Subsequent success saw Amgen offer an IPO to list on NASDAQ in 1983. The stock trades under AMGN as its symbol. Since its founding, Amgen has its headquarters in Thousand Oaks, California.

Amgen is a major player in the global healthcare industry where it produces human therapeutics for users from across the globe. Some of the most popular products from Amgen include Enbrel, which treats arthritis and psoriasis; Neulasta, which targets cancer patients, and Prolia, which treats osteoporosis in postmenopausal women. The market for Amgen’s products includes healthcare facilities, physicians, pharmacies, and clinics. The company operates collaboratively with industry greats like Bayer HealthCare Pharmaceuticals Inc. and Novartis.

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.